What is the latest price of Pralsetinib in 2023?

Pralsetinib (Pralsetinib) is indicated alone for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who have not received RET inhibitor therapy during the transfusion period and who are RET fusion positive. In a phase I/II study, platinib was associated with an overall response of 64% in patients with RET-positive cancers, and response rates of 57% and 70%, respectively, in patients who had received prior platinum-based chemotherapy or chemotherapy.

Non-small cell lung cancer is a rare tumor caused by chromosomal changes that result in the fusion of the RET gene with other genes such as KIF5B and CCDC6. Until recently, patients received platinum-based chemotherapy or multivariable tyrosine kinase inhibitors, but response rates with these drugs were not high due to their nonspecific mechanism of action. Clinicians treating patients with platinib should monitor for fatigue, hepatotoxicity, bleeding events, hypertension, myelosuppression, fever, and respiratory tract infections, as these may require treatment discontinuation, dose reduction, or discontinuation of therapy.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.